June 15, 2022
Please click here to register!
Timing:
8:00 am (PT)
11:00 am (ET)
4:00 pm (GMT)
5:00 pm (CET)
6:00 pm (IST)
12:00 pm (Beijing)
01:00 am (Tokyo, Seoul)
Summary of the presentation:
ICH M12 Draft Guidance on Drug Interaction Studies
In June 2022, the ICH released their M12 harmonized draft guideline on Drug Interaction Studies. The ICH, International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, aims to harmonize guidelines released by multiple regulatory agencies for the same purpose in order to create a single reference document that can be applied across borders. The ICH M12 will ultimately become the standard guidance for Sponsors developing compounds from pre-clinical through final submission for registration. The guideline covers both in vitro and clinical drug metabolizing enzyme- and transporter-mediated drug-drug interactions by providing recommendations to support investigations and data interpretation. In this webinar, we are going to walk through the main elements of a DDI investigation study with a focus on changes in this new guidance compared to those previously published by FDA, EMA, and PMDA, and other regulatory documents. The regulatory list of drug metabolizing enzymes and transporters will be discussed, including considerations for selecting assay systems and conditions, and data interpretation guidelines. As currently the ICH M12 is a draft guidance released for public feedback and commentary, we also aim to address some of the recommendations based on our experience as a CRO experience and share our initial thoughts. The presentation will be followed by a Q&A session and panel discussion with multiple senior SOLVO colleagues on board to address our first impressions of the new guidelines and discuss future perspectives.
Next entry: Scientific News
Previous entry: Webinar Announcement - Join us on 22 June, Wednesday!